Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 705

1.

Visual snow syndrome: A clinical and phenotypical description of 1,100 cases.

Puledda F, Schankin C, Goadsby PJ.

Neurology. 2020 Jan 15. pii: 10.1212/WNL.0000000000008909. doi: 10.1212/WNL.0000000000008909. [Epub ahead of print]

PMID:
31941797
2.

Imaging the Visual Network in the Migraine Spectrum.

Puledda F, Ffytche D, O'Daly O, Goadsby PJ.

Front Neurol. 2019 Dec 13;10:1325. doi: 10.3389/fneur.2019.01325. eCollection 2019. Review.

3.

Migraine: a brain state amenable to therapy.

Eller M, Goadsby PJ.

Med J Aust. 2020 Jan;212(1):32-39. doi: 10.5694/mja2.50435. Epub 2019 Dec 6. Review.

PMID:
31808561
4.

Biochemical Modulation and Pathophysiology of Migraine.

Chan C, Wei DY, Goadsby PJ.

J Neuroophthalmol. 2019 Dec;39(4):470-479. doi: 10.1097/WNO.0000000000000875.

PMID:
31714319
5.

Safety and efficacy of sphenopalatine ganglion stimulation for chronic cluster headache: a double-blind, randomised controlled trial.

Goadsby PJ, Sahai-Srivastava S, Kezirian EJ, Calhoun AH, Matthews DC, McAllister PJ, Costantino PD, Friedman DI, Zuniga JR, Mechtler LL, Popat SR, Rezai AR, Dodick DW.

Lancet Neurol. 2019 Dec;18(12):1081-1090. doi: 10.1016/S1474-4422(19)30322-9.

PMID:
31701891
6.

Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials.

Ruff DD, Ford JH, Tockhorn-Heidenreich A, Stauffer VL, Govindan S, Aurora SK, Terwindt GM, Goadsby PJ.

Eur J Neurol. 2019 Nov 6. doi: 10.1111/ene.14114. [Epub ahead of print]

PMID:
31692188
7.

Migraine progression in subgroups of migraine based on comorbidities: Results of the CaMEO Study.

Lipton RB, Fanning KM, Buse DC, Martin VT, Hohaia LB, Adams AM, Reed ML, Goadsby PJ.

Neurology. 2019 Dec 10;93(24):e2224-e2236. doi: 10.1212/WNL.0000000000008589. Epub 2019 Nov 5.

PMID:
31690685
8.

An Update: Pathophysiology of Migraine.

Goadsby PJ, Holland PR.

Neurol Clin. 2019 Nov;37(4):651-671. doi: 10.1016/j.ncl.2019.07.008. Review.

PMID:
31563225
9.

Recent Advances in Pharmacotherapy for Episodic Migraine.

Chan C, Goadsby PJ.

CNS Drugs. 2019 Nov;33(11):1053-1071. doi: 10.1007/s40263-019-00665-9.

PMID:
31556018
10.

Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults.

Goadsby PJ, Tepper SJ, Watkins PB, Ayele G, Miceli R, Butler M, Severt L, Finnegan M, Szegedi A, Trugman JM, Jakate A.

Cephalalgia. 2019 Dec;39(14):1753-1761. doi: 10.1177/0333102419869918. Epub 2019 Sep 19.

11.

Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial.

Diener HC, Goadsby PJ, Ashina M, Al-Karagholi MA, Sinclair A, Mitsikostas D, Magis D, Pozo-Rosich P, Irimia Sieira P, Làinez MJ, Gaul C, Silver N, Hoffmann J, Marin J, Liebler E, Ferrari MD.

Cephalalgia. 2019 Oct;39(12):1475-1487. doi: 10.1177/0333102419876920. Epub 2019 Sep 15.

12.

Aura and Head pain: relationship and gaps in the translational models.

Bolay H, Vuralli D, Goadsby PJ.

J Headache Pain. 2019 Sep 3;20(1):94. doi: 10.1186/s10194-019-1042-8. Review.

13.

Primary headache disorders: Five new things.

Goadsby PJ.

Neurol Clin Pract. 2019 Jun;9(3):233-240. doi: 10.1212/CPJ.0000000000000654.

14.

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.

Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB.

Lancet. 2019 Aug 31;394(10200):737-745. doi: 10.1016/S0140-6736(19)31606-X. Epub 2019 Jul 13.

PMID:
31311674
15.

Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.

Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ.

N Engl J Med. 2019 Jul 11;381(2):142-149. doi: 10.1056/NEJMoa1811090.

PMID:
31291516
16.

Trial of Galcanezumab in Prevention of Episodic Cluster Headache.

Goadsby PJ, Dodick DW, Leone M, Bardos JN, Oakes TM, Millen BA, Zhou C, Dowsett SA, Aurora SK, Ahn AH, Yang JY, Conley RR, Martinez JM.

N Engl J Med. 2019 Jul 11;381(2):132-141. doi: 10.1056/NEJMoa1813440.

PMID:
31291515
17.

Targeting CGRP and 5-HT1F Receptors for the Acute Therapy of Migraine: A Literature Review.

Moreno-Ajona D, Chan C, Villar-Martínez MD, Goadsby PJ.

Headache. 2019 Jul;59 Suppl 2:3-19. doi: 10.1111/head.13582. Review.

PMID:
31291016
18.

Managing cluster headache.

Wei DY, Khalil M, Goadsby PJ.

Pract Neurol. 2019 Dec;19(6):521-528. doi: 10.1136/practneurol-2018-002124. Epub 2019 Jul 5.

19.

Differential efficacy of non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A meta-analysis.

de Coo IF, Marin JC, Silberstein SD, Friedman DI, Gaul C, McClure CK, Tyagi A, Liebler E, Tepper SJ, Ferrari MD, Goadsby PJ.

Cephalalgia. 2019 Jul;39(8):967-977. doi: 10.1177/0333102419856607. Epub 2019 Jun 10.

20.

Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial.

Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J, Cady R, Smith J.

Cephalalgia. 2019 Aug;39(9):1075-1085. doi: 10.1177/0333102419858355. Epub 2019 Jun 24.

PMID:
31234642
21.

The Association Between Parental Migraine and Infant Colic: A Cross-Sectional, Web-Based, U.S. Survey Study.

Gelfand AA, Buse DC, Cabana MD, Grimes B, Goadsby PJ, Allen IE.

Headache. 2019 Jul;59(7):988-1001. doi: 10.1111/head.13575. Epub 2019 Jun 20.

PMID:
31222745
22.

Trigeminal autonomic cephalalgias presenting in a multidisciplinary tertiary orofacial pain clinic.

Wei DY, Moreno-Ajona D, Renton T, Goadsby PJ.

J Headache Pain. 2019 Jun 11;20(1):69. doi: 10.1186/s10194-019-1019-7.

23.

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine.

Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick D, Rippon GA, Klatt J, Xue F, Chia V, Zhang F, Cheng S, Mikol DD.

Cephalalgia. 2019 Oct;39(11):1455-1464. doi: 10.1177/0333102419854082. Epub 2019 May 30.

24.

James W. Lance MD.

Goadsby PJ.

Headache. 2019 Jun;59(6):825-827. doi: 10.1111/head.13552. No abstract available.

PMID:
31144299
25.

Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.

Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, Gaul C.

Brain. 2019 Jul 1;142(7):1894-1904. doi: 10.1093/brain/awz134.

26.

Marco Polo of Australian neurology.

Kiernan MC, Goadsby PJ, Burke D.

J Neurol Neurosurg Psychiatry. 2019 Jun;90(6):627-628. doi: 10.1136/jnnp-2019-320989. Epub 2019 May 2. No abstract available.

PMID:
31048340
27.

N-Methyl-d-aspartate receptor open-channel blockers memantine and magnesium modulate nociceptive trigeminovascular neurotransmission in rats.

Hoffmann J, Storer RJ, Park JW, Goadsby PJ.

Eur J Neurosci. 2019 Sep;50(5):2847-2859. doi: 10.1111/ejn.14423. Epub 2019 Jun 3.

PMID:
31009120
28.

Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis.

Goadsby PJ, Dodick DW, Martinez JM, Ferguson MB, Oakes TM, Zhang Q, Skljarevski V, Aurora SK.

J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):939-944. doi: 10.1136/jnnp-2018-320242. Epub 2019 Apr 19.

29.

Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.

Goadsby PJ, Paemeleire K, Broessner G, Brandes J, Klatt J, Zhang F, Picard H, Lenz R, Mikol DD.

Cephalalgia. 2019 Jun;39(7):817-826. doi: 10.1177/0333102419835459. Epub 2019 Apr 13.

PMID:
30982348
30.

The discovery and development of inhaled therapeutics for migraine.

Vandenbussche N, Goadsby PJ.

Expert Opin Drug Discov. 2019 Jun;14(6):591-599. doi: 10.1080/17460441.2019.1598373. Epub 2019 Mar 29.

PMID:
30924698
31.

Health state utilities associated with attributes of migraine preventive treatments based on patient and general population preferences.

Matza LS, Deger KA, Vo P, Maniyar F, Goadsby PJ.

Qual Life Res. 2019 Sep;28(9):2359-2372. doi: 10.1007/s11136-019-02163-3. Epub 2019 Mar 28.

32.

Dr James Lance, Professor of Neurology in Sydney, Australia, died on 20 February 2019, age 92.

Edvinsson L, Evers S, Goadsby PJ.

Cephalalgia. 2019 Apr;39(5):681-682. doi: 10.1177/0333102419840639. Epub 2019 Mar 21. No abstract available.

PMID:
30897943
33.

Author response: Gray matter volume modifications in migraine: A cross-sectional and longitudinal study.

Filippi M, Messina R, Goadsby PJ, Rocca MA.

Neurology. 2019 Mar 19;92(12):587-588. doi: 10.1212/WNL.0000000000007132. No abstract available.

PMID:
30886079
34.

Discovery of CGRP in relation to migraine.

Edvinsson L, Goadsby PJ.

Cephalalgia. 2019 Mar;39(3):331-332. doi: 10.1177/0333102418779544. No abstract available.

PMID:
30827155
35.

Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition.

Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ, Mandrekar J; International Headache Society Clinical Trials Standing Committee.

Cephalalgia. 2019 May;39(6):687-710. doi: 10.1177/0333102419828967. Epub 2019 Feb 26.

36.

Teaching NeuroImages: Greater occipital nerve injection: A cautionary tale.

Wei DY, Connor S, Goadsby PJ.

Neurology. 2019 Feb 12;92(7):e746-e747. doi: 10.1212/WNL.0000000000006929. No abstract available.

PMID:
30745452
37.

Lorcaserin Safety in Overweight or Obese Patients.

Vandenbussche N, Goadsby PJ.

N Engl J Med. 2019 Jan 3;380(1):99. doi: 10.1056/NEJMc1813971. No abstract available.

PMID:
30601744
38.

Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity.

Akerman S, Karsan N, Bose P, Hoffmann JR, Holland PR, Romero-Reyes M, Goadsby PJ.

Brain. 2019 Jan 1;142(1):103-119. doi: 10.1093/brain/awy313.

39.

Cortical abnormalities in episodic migraine: A multi-center 3T MRI study.

Magon S, May A, Stankewitz A, Goadsby PJ, Schankin C, Ashina M, Amin FM, Seifert CL, Mallar Chakravarty M, Müller J, Sprenger T.

Cephalalgia. 2019 Apr;39(5):665-673. doi: 10.1177/0333102418795163. Epub 2018 Dec 10.

PMID:
30525946
40.

Biological insights from the premonitory symptoms of migraine.

Karsan N, Goadsby PJ.

Nat Rev Neurol. 2018 Dec;14(12):699-710. doi: 10.1038/s41582-018-0098-4. Review.

PMID:
30448858
41.

Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study.

Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK.

Neurology. 2018 Dec 11;91(24):e2211-e2221. doi: 10.1212/WNL.0000000000006640. Epub 2018 Nov 16.

42.

Divergent influences of the locus coeruleus on migraine pathophysiology.

Vila-Pueyo M, Strother LC, Kefel M, Goadsby PJ, Holland PR.

Pain. 2019 Feb;160(2):385-394. doi: 10.1097/j.pain.0000000000001421.

43.

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.

Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, Klatt J.

Lancet. 2018 Nov 24;392(10161):2280-2287. doi: 10.1016/S0140-6736(18)32534-0. Epub 2018 Oct 22.

PMID:
30360965
44.

Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and Adolescents.

Szperka CL, VanderPluym J, Orr SL, Oakley CB, Qubty W, Patniyot I, Lagman-Bartolome AM, Morris C, Gautreaux J, Victorio MC, Hagler S, Narula S, Candee MS, Cleves-Bayon C, Rao R, Fryer RH, Bicknese AR, Yonker M, Hershey AD, Powers SW, Goadsby PJ, Gelfand AA.

Headache. 2018 Nov;58(10):1658-1669. doi: 10.1111/head.13414. Epub 2018 Oct 15. No abstract available.

45.

Prolonged migraine aura: new insights from a prospective diary-aided study.

Viana M, Sances G, Linde M, Nappi G, Khaliq F, Goadsby PJ, Tassorelli C.

J Headache Pain. 2018 Aug 31;19(1):77. doi: 10.1186/s10194-018-0910-y.

46.

The Migraine Postdrome.

Bose P, Karsan N, Goadsby PJ.

Continuum (Minneap Minn). 2018 Aug;24(4, Headache):1023-1031. doi: 10.1212/CON.0000000000000626. Review.

PMID:
30074547
47.

The Migraine Premonitory Phase.

Karsan N, Bose P, Goadsby PJ.

Continuum (Minneap Minn). 2018 Aug;24(4, Headache):996-1008. doi: 10.1212/CON.0000000000000624. Review.

PMID:
30074545
48.

Identifying Natural Subgroups of Migraine Based on Comorbidity and Concomitant Condition Profiles: Results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.

Lipton RB, Fanning KM, Buse DC, Martin VT, Reed ML, Manack Adams A, Goadsby PJ.

Headache. 2018 Jul;58(7):933-947. doi: 10.1111/head.13342. Epub 2018 Jul 19.

PMID:
30024028
49.

Cluster Headache and Calcitonin Gene-Related Peptide-More on Quantum Therapeutics in Headache Medicine.

Gelfand AA, Goadsby PJ.

JAMA Neurol. 2018 Oct 1;75(10):1179-1180. doi: 10.1001/jamaneurol.2018.1428. No abstract available.

PMID:
29987331
50.

Recent advances in headache neuroimaging.

Messina R, Filippi M, Goadsby PJ.

Curr Opin Neurol. 2018 Aug;31(4):379-385. doi: 10.1097/WCO.0000000000000573. Review.

PMID:
29952833

Supplemental Content

Loading ...
Support Center